Particularly, in addition to multiple known AD markers that were affected by MS1262 treatment such as IL-33, complement C3, CD109, ADCYAP1, PBXIP1, CTHRC1, GFAP, OLFM3, and the protein products of 33 AD-risk genes (Fig. 6Aand Data S5C),106 MS1262 treatment reversed the expression or phosphorylation of SMOC1 and other proteins in the matrisome that were recently characterized as CSF biomarkers of early stage AD 28 (Figs. 6B & 7E). This evidence concerns the gene IL33 and Alzheimer disease.